Identification

Name
Capric acid
Accession Number
DB03600  (EXPT01213, DB03838)
Type
Small Molecule
Groups
Experimental
Description

Decanoic acid is a solid. This compound belongs to the straight chain fatty acids. These are fatty acids with a straight aliphatic chain. The proteins that decanoic acid targets include furin, octanoyltransferase, 3-oxoacyl-[acyl-carrier-protein] synthase 1, peptostreptococcal albumin-binding protein, and putative uncharacterized protein tcp14.

Structure
Thumb
Synonyms
  • 1-nonanecarboxylic acid
  • Decanoic acid
  • N-capric acid
  • N-decanoic acid
External IDs
FEMA NO. 2364 / NSC-5025 / PALMAC-99-10 / PRIFAC-2906
Categories
UNII
4G9EDB6V73
CAS number
334-48-5
Weight
Average: 172.2646
Monoisotopic: 172.146329884
Chemical Formula
C10H20O2
InChI Key
GHVNFZFCNZKVNT-UHFFFAOYSA-N
InChI
InChI=1S/C10H20O2/c1-2-3-4-5-6-7-8-9-10(11)12/h2-9H2,1H3,(H,11,12)
IUPAC Name
decanoic acid
SMILES
CCCCCCCCCC(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U3-oxoacyl-[acyl-carrier-protein] synthase 1Not AvailableEscherichia coli (strain K12)
UFurinNot AvailableHuman
UPeptostreptococcal albumin-binding proteinNot AvailablePeptostreptococcus magnus
UGlycolipid transfer proteinNot AvailableHuman
UOctanoyltransferaseNot AvailableMycobacterium tuberculosis
UPutative uncharacterized protein tcp14Not AvailableActinoplanes teichomyceticus
UPeroxisome proliferator-activated receptor gamma
ligand
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Fatty Acid BiosynthesisMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmlodipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Capric acid.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Capric acid is combined with Amrinone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Capric acid is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Barnidipine.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Capric acid is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Capric acid is combined with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Capric acid.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Capric acid.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Capric acid is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Capric acid is combined with Caroverine.Experimental
CilnidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Capric acid is combined with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Capric acid.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Capric acid.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Capric acid.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Capric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Capric acid is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Capric acid.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Capric acid.Approved
DotarizineThe risk or severity of adverse effects can be increased when Capric acid is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Efonidipine.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Capric acid is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Capric acid.Approved
FelodipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Capric acid is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Capric acid is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Capric acid can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Capric acid is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Capric acid is combined with Gallopamil.Investigational
IsradipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Capric acid is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Lercanidipine.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Capric acid is combined with Lidoflazine.Experimental
LosartanThe metabolism of Losartan can be decreased when combined with Capric acid.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Capric acid is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Manidipine.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Capric acid is combined with Mibefradil.Investigational, Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Capric acid is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Capric acid is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Capric acid is combined with Nitrendipine.Approved, Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Capric acid is combined with Otilonium.Experimental, Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Capric acid is combined with Perhexiline.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Capric acid.Approved, Vet Approved
PimozideCapric acid may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Capric acid is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Capric acid is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Capric acid is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Capric acid.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Capric acid.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Capric acid.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Capric acid.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Capric acid.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Capric acid.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Capric acid.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Capric acid is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Capric acid.Approved
SucralfateSucralfate can cause a decrease in the absorption of Capric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Capric acid.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Capric acid.Approved, Investigational
TerodilineThe risk or severity of adverse effects can be increased when Capric acid is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Capric acid is combined with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Capric acid is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Capric acid is combined with Tranilast.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Capric acid is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Capric acid is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Capric acid is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Capric acid is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Capric acid.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB00511
KEGG Compound
C01571
PubChem Compound
2969
PubChem Substance
46509055
ChemSpider
2863
ChEBI
30813
ChEMBL
CHEMBL107498
HET
DKA
PDB Entries
1e7e / 1f91 / 1fk0 / 1gxs / 1p8j / 1qqs / 1t5m / 1t5n / 1tf0 / 1tfj
show 20 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)31.9 °CPhysProp
boiling point (°C)268.7 °CPhysProp
water solubility61.8 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.09HANSCH,C ET AL. (1995)
logS-3.44ADME Research, USCD
pKa4.9BARRATT,MD (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0946 mg/mLALOGPS
logP3.93ALOGPS
logP3.59ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)4.95ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity49.48 m3·mol-1ChemAxon
Polarizability21.61 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9888
Blood Brain Barrier+0.9488
Caco-2 permeable+0.8326
P-glycoprotein substrateNon-substrate0.6321
P-glycoprotein inhibitor INon-inhibitor0.9598
P-glycoprotein inhibitor IINon-inhibitor0.9277
Renal organic cation transporterNon-inhibitor0.9266
CYP450 2C9 substrateNon-substrate0.7886
CYP450 2D6 substrateNon-substrate0.8956
CYP450 3A4 substrateNon-substrate0.6982
CYP450 1A2 substrateInhibitor0.8326
CYP450 2C9 inhibitorNon-inhibitor0.8808
CYP450 2D6 inhibitorNon-inhibitor0.9554
CYP450 2C19 inhibitorNon-inhibitor0.9578
CYP450 3A4 inhibitorNon-inhibitor0.9484
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9647
Ames testNon AMES toxic0.9865
CarcinogenicityNon-carcinogens0.6452
BiodegradationReady biodegradable0.8795
Rat acute toxicity1.3275 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9322
hERG inhibition (predictor II)Non-inhibitor0.8868
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-017i-2920000000-7f6721f01b80a790d544
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-076u-9000000000-96a2e9e00e464db3c086
GC-MS Spectrum - GC-MSGC-MSsplash10-017i-2920000000-7f6721f01b80a790d544
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-016r-1910000000-1cc1026f6f325d994ab4
Mass Spectrum (Electron Ionization)MSsplash10-074l-9100000000-bf788cb34c09c6af56bf
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-00di-0900000000-0a7f944302bce161f7e5
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-00b9-1900000000-b68efbceecf3433a9995
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-005a-9600000000-f2a54ed1a56ee9b7af77
MS/MS Spectrum - EI-B (HITACHI M-80B) , PositiveLC-MS/MSsplash10-076u-9000000000-96a2e9e00e464db3c086
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-00di-0900000000-771e7907916bf05e6b10
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-00di-0900000000-f1e000384728ee06f802
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-00di-1900000000-42a901bb54546da030da
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-004i-9000000000-83e77de04461ded1c4bc
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-004i-9000000000-f3190b828218d04d3cc7
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0900000000-856f34ef153b15cb3d1d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0adi-4900000000-efb0bd73973bf0c317fd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-9000000000-d81148541fa575d32552
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0900000000-99cd0519b210c46b4a4c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fmi-1900000000-209285ec682ca47e1e5d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9300000000-fb697080d761d0f48fe2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0900000000-856f34ef153b15cb3d1d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0adi-4900000000-efb0bd73973bf0c317fd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-9000000000-d81148541fa575d32552
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0900000000-99cd0519b210c46b4a4c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fmi-1900000000-209285ec682ca47e1e5d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9300000000-fb697080d761d0f48fe2
MS/MS Spectrum - ESI-TOF 10V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 10V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-0900000000-771e7907916bf05e6b10
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-0900000000-f1e000384728ee06f802
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-1900000000-d5dbc60c65c1a7d34e2f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004i-9000000000-83e77de04461ded1c4bc
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004i-9000000000-f3190b828218d04d3cc7
LC-MS/MS Spectrum - LC-ESI-IT , negativeLC-MS/MSsplash10-00di-0900000000-53ea38eb25eaea66d22a
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-00di-0900000000-8c6cdf0491f51ba6ef26
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-00di-0900000000-3afa642872e4450f0c49
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0900000000-3eb3455ff5fbfa8a3a2c
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Medium-chain fatty acids
Alternative Parents
Straight chain fatty acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Medium-chain fatty acid / Straight chain fatty acid / Monocarboxylic acid or derivatives / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
medium-chain fatty acid, straight-chain saturated fatty acid (CHEBI:30813) / Straight chain fatty acids, Saturated fatty acids (C01571) / Straight chain fatty acids (LMFA01010010)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
3-oxoacyl-[acyl-carrier-protein] synthase activity
Specific Function
Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Specific for elongation from C-10 to unsaturated C-16 and C-18 fatty...
Gene Name
fabB
Uniprot ID
P0A953
Uniprot Name
3-oxoacyl-[acyl-carrier-protein] synthase 1
Molecular Weight
42612.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Furin is likely to represent the ubiquitous endoprotease activity within constitutive secretory pathways and capable of cleavage at the RX(K/R)R consensus motif.
Gene Name
FURIN
Uniprot ID
P09958
Uniprot Name
Furin
Molecular Weight
86677.375 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Peptostreptococcus magnus
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Binds serum albumin.
Gene Name
pab
Uniprot ID
Q51911
Uniprot Name
Peptostreptococcal albumin-binding protein
Molecular Weight
43057.45 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Lipid binding
Specific Function
Accelerates the intermembrane transfer of various glycolipids. Catalyzes the transfer of various glycosphingolipids between membranes but does not catalyze the transfer of phospholipids. May be inv...
Gene Name
GLTP
Uniprot ID
Q9NZD2
Uniprot Name
Glycolipid transfer protein
Molecular Weight
23849.6 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
Catalyzes the transfer of endogenously produced octanoic acid from octanoyl-acyl-carrier-protein onto the lipoyl domains of lipoate-dependent enzymes. Lipoyl-ACP can also act as a substrate although octanoyl-ACP is likely to be the physiological substrate.
Specific Function
Lipoyl(octanoyl) transferase activity
Gene Name
lipB
Uniprot ID
P9WK83
Uniprot Name
Octanoyltransferase
Molecular Weight
24210.415 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Actinoplanes teichomyceticus
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Not Available
Gene Name
tcp14
Uniprot ID
Q6ZZJ1
Uniprot Name
Putative uncharacterized protein tcp14
Molecular Weight
30067.18 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Ligand
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Zhang L, Ren XM, Wan B, Guo LH: Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor gamma. Toxicol Appl Pharmacol. 2014 Sep 15;279(3):275-83. doi: 10.1016/j.taap.2014.06.020. Epub 2014 Jul 3. [PubMed:24998974]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kenyon MA, Hamilton JA: 13C NMR studies of the binding of medium-chain fatty acids to human serum albumin. J Lipid Res. 1994 Mar;35(3):458-67. [PubMed:8014580]
  2. Vorum H, Pedersen AO, Honore B: Fatty acid and drug binding to a low-affinity component of human serum albumin, purified by affinity chromatography. Int J Pept Protein Res. 1992 Nov;40(5):415-22. [PubMed:1483836]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:30